Study on analgesic effect and depression state of esketamine combined with sufentanil after cesarean section

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053376

Enrollment

Unknown

Registered

2021-11-20

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean section patients

Interventions

Control group:Sufentanil 3.0 µg / kg + Tropisetron Hydrochloride 10 mg

Experimental group1:Sufentanil 2.5µg / kg + Esketamine 0.5mg / kg + Tropisetron Hydrochloride 10mg

Experimental group2:Sufentanil 2.0µg / kg + Esketamine 1.0mg / kg + Tropisetron Hydrochloride 10mg

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. 90 singleton pregnant women requiring cesarean section; 2. Aged 20 to 35 years, ASA grade I to II.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to any component of ketamine hydrochloride; 2. Patients with hypertension and heart disease; 3. Those with a history of drug addiction and mental disorders.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale;Edinburgh Postnatal Depression Scale;Neonatal Behavioral Neurological Assessment;Exclusive Breastfeeding;Postoperative Adverse Reaction;	—

Countries

China

Contacts

Public ContactYao Linlin

Affiliated Hospital of Jining Medical University

yaolinlinmahua@163.com+86 15092662910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026